Sabine Tejpar Selected Research

Cetuximab (Erbitux)

1/2020	Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway.
12/2018	Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study.
2/2017	Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials.
1/2017	Feedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells.
1/2017	Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab.
1/2016	ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.
6/2015	FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study.
3/2015	Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.
12/2014	Personalized treatment is better than one treatment fits all in the management of patients with mCRC: a consensus statement.
9/2014	A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sabine Tejpar Research Topics

Disease

77	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 02/2005
74	Neoplasms (Cancer) 01/2022 - 04/2002
20	Colonic Neoplasms (Colon Cancer) 12/2022 - 02/2005
8	Neoplasm Metastasis (Metastasis) 12/2022 - 04/2009
8	Microsatellite Instability 01/2020 - 01/2009
7	Aggressive Fibromatosis (Desmoid) 01/2011 - 04/2002
4	Inflammation (Inflammations) 08/2021 - 06/2009
4	Carcinogenesis 01/2020 - 03/2005
4	Dupuytren Contracture (Dupuytrens Contracture) 04/2014 - 01/2009
2	Carcinoma (Carcinomatosis) 12/2021 - 11/2013
2	Fibrosis (Cirrhosis) 01/2021 - 04/2014
2	Melanoma (Melanoma, Malignant) 01/2021 - 01/2020
2	Adenocarcinoma 07/2012 - 06/2010
2	Disease Progression 05/2011 - 02/2005
2	Rectal Neoplasms (Rectal Cancer) 06/2009 - 02/2005
1	Adenoma (Adenomas) 12/2021
1	Ovarian Neoplasms (Ovarian Cancer) 11/2021
1	Wounds and Injuries (Trauma) 08/2021
1	COVID-19 01/2021
1	Dysbiosis 01/2020
1	Breast Neoplasms (Breast Cancer) 01/2020
1	Holoprosencephaly (Arhinencephaly) 01/2016
1	Neoplasm Micrometastasis 11/2015
1	Hemorrhage 10/2015
1	Arteriovenous Fistula 10/2015

Drug/Important Bio-Agent (IBA)

31	Cetuximab (Erbitux)FDA Link 01/2020 - 08/2007
28	Biomarkers (Surrogate Marker)IBA 11/2021 - 01/2009
26	ErbB Receptors (EGF Receptor)IBA 01/2017 - 05/2007
17	Irinotecan (Camptosar)FDA LinkGeneric 01/2020 - 04/2009
12	Fluorouracil (Carac)FDA LinkGeneric 01/2020 - 02/2005
11	Monoclonal AntibodiesIBA 01/2016 - 05/2009
10	Pharmaceutical PreparationsIBA 01/2022 - 06/2011
9	Proteins (Proteins, Gene)FDA Link 12/2021 - 03/2005
9	Leucovorin (Folinic Acid)FDA Link 01/2020 - 02/2005
7	Messenger RNA (mRNA)IBA 05/2016 - 03/2005
7	Formaldehyde (Formol)FDA Link 04/2016 - 09/2009
7	ParaffinIBA 04/2016 - 09/2009
6	Bevacizumab (Avastin)FDA Link 02/2017 - 09/2011
6	Biological ProductsIBA 01/2015 - 01/2009
5	AntibodiesIBA 01/2016 - 05/2007
5	DNA (Deoxyribonucleic Acid)IBA 03/2015 - 04/2002
5	beta CateninIBA 03/2009 - 01/2004
4	RNA (Ribonucleic Acid)IBA 01/2020 - 10/2007
4	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2020 - 05/2013
4	Panitumumab (Vectibix)FDA Link 05/2016 - 08/2010
4	MicroRNAs (MicroRNA)IBA 09/2014 - 09/2012
3	CytokinesIBA 11/2021 - 11/2016
3	Transcription Factors (Transcription Factor)IBA 01/2018 - 10/2007
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2017 - 09/2013
3	EpiregulinIBA 05/2016 - 10/2009
3	AmphiregulinIBA 05/2016 - 10/2009
3	LigandsIBA 05/2016 - 10/2009
3	Codon (Codons)IBA 03/2015 - 10/2010
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2014 - 01/2012
2	Cell-Free Nucleic AcidsIBA 01/2022 - 01/2021
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 01/2020
2	AntigensIBA 01/2021 - 01/2020
2	FurinIBA 01/2020 - 01/2015
2	Phosphotransferases (Kinase)IBA 01/2020 - 11/2013
2	Growth Factor ReceptorsIBA 01/2020 - 12/2013
2	EnzymesIBA 01/2019 - 01/2015
2	Transforming Growth Factor beta (TGF-beta)IBA 01/2018 - 08/2007
2	thiamine triphosphorate (TTP)IBA 05/2014 - 02/2005
2	Sorafenib (BAY 43-9006)FDA Link 11/2013 - 05/2013
2	Epidermal Growth Factor (EGF)IBA 12/2011 - 08/2007
2	Capecitabine (Xeloda)FDA Link 06/2009 - 02/2005
2	MagnesiumIBA 08/2007 - 05/2007
1	Poly I-CIBA 12/2022
1	InterferonsIBA 11/2021
1	Immune Checkpoint InhibitorsIBA 08/2021
1	InflammasomesIBA 01/2021
1	Adenosine Triphosphate (ATP)IBA 01/2021
1	nintedanibIBA 01/2021
1	CarcinogensIBA 10/2020
1	AzoxymethaneIBA 10/2020
1	AnthracyclinesIBA 01/2020
1	Bortezomib (Velcade)FDA Link 01/2020
1	Proprotein Convertases (Pro-Opiomelanocortin Converting Enzyme)IBA 01/2020
1	Matrix Metalloproteinases (MMPs)IBA 01/2020
1	Small Cytoplasmic RNAIBA 01/2020
1	Interleukin-22 (IL-22)IBA 01/2020
1	bcl-X ProteinIBA 01/2018
1	Valine (L-Valine)FDA Link 01/2017
1	DNA Polymerase IIIBA 11/2016
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 05/2016
1	Small Interfering RNA (siRNA)IBA 04/2016
1	Type I DNA Topoisomerases (Topoisomerase I)IBA 04/2016
1	Smad4 ProteinIBA 01/2016
1	Transforming Growth Factors (Transforming Growth Factor)IBA 11/2015
1	EmulsionsIBA 03/2015

Therapy/Procedure

35	Therapeutics 08/2021 - 01/2009
19	Drug Therapy (Chemotherapy) 01/2022 - 05/2007
6	Adjuvant Chemotherapy 12/2022 - 02/2005
6	Precision Medicine 01/2018 - 03/2014
5	Immunotherapy 11/2021 - 01/2020
4	Radiotherapy 08/2021 - 02/2005
2	Fasciotomy 04/2014 - 06/2011
1	Conservative Treatment 10/2015
1	Catheters 10/2015
1	Therapeutic Embolization 10/2015